tetano
Editor, Senior Moderator
J Crohns Colitis. 2015 Sep 7. pii: jjv152. [Epub ahead of print]
[h=1]Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and/or biologics: a two-year prospective study.[/h] Launay O[SUP]1[/SUP], Abitbol V[SUP]2[/SUP], Krivine A[SUP]3[/SUP], Ben Slama L[SUP]4[/SUP], Bourreille A[SUP]5[/SUP], Dupas JL[SUP]6[/SUP], H?buterne X[SUP]7[/SUP], Savoye G[SUP]8[/SUP], Deplanque D[SUP]9[/SUP], Bouhnik Y[SUP]10[/SUP], Pelletier AL[SUP]11[/SUP], Galtier F[SUP]12[/SUP], Laharie D[SUP]13[/SUP], Nachury M[SUP]14[/SUP], Zerbib F[SUP]15[/SUP], Allez M[SUP]16[/SUP], Bommelaer G[SUP]17[/SUP], Duclos B[SUP]18[/SUP], Lucht F[SUP]19[/SUP], Gougeon ML[SUP]20[/SUP], Tartour E[SUP]21[/SUP], Rozenberg F[SUP]22[/SUP], Hanslik T[SUP]23[/SUP], Beaugerie L[SUP]24[/SUP], Carrat F[SUP]25[/SUP]; MICIVAX Study Group.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND AND AIMS:[/h] Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults.
[h=4]METHODS:[/h] A multicenter prospective study performed in 255 IBD adults (18-64 years) receiving the trivalent influenza vaccine for years 2009-2010 and 2010-2011. Haemagglutination inhibition (HI) titres assessed before, 3 weeks and 6 months post-vaccination.
[h=4]RESULTS:[/h] At inclusion, 31 patients had no IS (Group A), 77 IS without anti-TNF (Group B) and 117 anti-TNF with or without IS (Group C). Three weeks after the first vaccination, rates of seroprotection were 77%, 75% and 66% for A/H1N12007 strain (p=0.35), 77%, 68% and 52% for A/H3N2 strain (p=0.014) and 97%, 96% and 95% for B strain (p=0.99) in groups A, B, and C, respectively. Seroconversion rates for A/H1N12007 strain (67%, 64%, 54%; p=0.28), A/H3N2 strain (63%, 50%, 41%; p=0.074) and B strain (63%, 76%, 60%; p=0.078) were not significantly different according to treatment group. At 6 months after vaccination, seroprotection rates were lower in Group C compared to Group A and B. Comparable results were observed for the second year of vaccination. No impact on Harvey-Bradshaw and Mayo scores has been detectedConclusions:Influenza vaccine yielded high seroprotection rates in IBD patients. Persistence of seroprotection was lower in patients with anti-TNF.ClinicalTrials.gov, Number NCT01022749.
Copyright ? 2015 European Crohn?s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
[h=4]KEYWORDS:[/h] Vaccine immune response; anti-TNF; safety
PMID: 26351392 [PubMed - as supplied by publisher]
[h=1]Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and/or biologics: a two-year prospective study.[/h] Launay O[SUP]1[/SUP], Abitbol V[SUP]2[/SUP], Krivine A[SUP]3[/SUP], Ben Slama L[SUP]4[/SUP], Bourreille A[SUP]5[/SUP], Dupas JL[SUP]6[/SUP], H?buterne X[SUP]7[/SUP], Savoye G[SUP]8[/SUP], Deplanque D[SUP]9[/SUP], Bouhnik Y[SUP]10[/SUP], Pelletier AL[SUP]11[/SUP], Galtier F[SUP]12[/SUP], Laharie D[SUP]13[/SUP], Nachury M[SUP]14[/SUP], Zerbib F[SUP]15[/SUP], Allez M[SUP]16[/SUP], Bommelaer G[SUP]17[/SUP], Duclos B[SUP]18[/SUP], Lucht F[SUP]19[/SUP], Gougeon ML[SUP]20[/SUP], Tartour E[SUP]21[/SUP], Rozenberg F[SUP]22[/SUP], Hanslik T[SUP]23[/SUP], Beaugerie L[SUP]24[/SUP], Carrat F[SUP]25[/SUP]; MICIVAX Study Group.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND AND AIMS:[/h] Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults.
[h=4]METHODS:[/h] A multicenter prospective study performed in 255 IBD adults (18-64 years) receiving the trivalent influenza vaccine for years 2009-2010 and 2010-2011. Haemagglutination inhibition (HI) titres assessed before, 3 weeks and 6 months post-vaccination.
[h=4]RESULTS:[/h] At inclusion, 31 patients had no IS (Group A), 77 IS without anti-TNF (Group B) and 117 anti-TNF with or without IS (Group C). Three weeks after the first vaccination, rates of seroprotection were 77%, 75% and 66% for A/H1N12007 strain (p=0.35), 77%, 68% and 52% for A/H3N2 strain (p=0.014) and 97%, 96% and 95% for B strain (p=0.99) in groups A, B, and C, respectively. Seroconversion rates for A/H1N12007 strain (67%, 64%, 54%; p=0.28), A/H3N2 strain (63%, 50%, 41%; p=0.074) and B strain (63%, 76%, 60%; p=0.078) were not significantly different according to treatment group. At 6 months after vaccination, seroprotection rates were lower in Group C compared to Group A and B. Comparable results were observed for the second year of vaccination. No impact on Harvey-Bradshaw and Mayo scores has been detectedConclusions:Influenza vaccine yielded high seroprotection rates in IBD patients. Persistence of seroprotection was lower in patients with anti-TNF.ClinicalTrials.gov, Number NCT01022749.
Copyright ? 2015 European Crohn?s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
[h=4]KEYWORDS:[/h] Vaccine immune response; anti-TNF; safety
PMID: 26351392 [PubMed - as supplied by publisher]